Skip to content

Replimune Group REPL Financing Cash Flow

Financing Cash Flow at other companies

Amgen logo
AmgenAMGN
$1.44B+135%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$802.2M+26.3%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$75.46M-24.4%
Immunome logo
ImmunomeIMNM
-$135K-100%
CG Oncology logo
CG OncologyCGON
$393M+87,233%
Erasca, Inc. logo
Erasca, Inc.ERAS
$244.66M+741,306%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$919.03M+28.6%
Enterprise value$873.59M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's financing cash flow?
Replimune Group (REPL) reported financing cash flow of $10.45M in Q4 2025.
How has Replimune Group's financing cash flow changed year-over-year?
Replimune Group's financing cash flow decreased by 93.3% year-over-year, from $155.93M to $10.45M.
What is the long-term trend for Replimune Group's financing cash flow?
Over 2 years (2022 to 2024), Replimune Group's financing cash flow has grown at a 57.7% compound annual growth rate (CAGR), from $6.6M to $16.41M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.